7-(4-acetyl-2-ethyl-5-hydroxyphenoxy)-2,2-dimethylheptanenitrile | 117690-81-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-(4-acetyl-2-ethyl-5-hydroxyphenoxy)-2,2-dimethylheptanenitrile
• CAS: 117690-81-0
• 化学式: C₁₉H₂₇NO₃
• 分子量: 317.428
• InChiKey: AAJFXRIGBIFCRC-UHFFFAOYSA-N

物化性质

• 沸点：
  508.0±50.0 °C(Predicted)
• 密度：
  1.052±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(4-acetyl-2-ethyl-5-hydroxyphenoxy)-2,2-dimethylheptanenitrile 在 叠氮基三甲基硅烷 、 tetra-n-butylammoniumfluoride trihydrate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以72%的产率得到1-[5-乙基-2-羟基-4-[[6-甲基-6-(1H-四唑-5-基)庚基]氧基]苯基]乙酮
  参考文献：
  名称：

  Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists

  摘要：

  Compound 1 (IC50 = 35.2 +/- 7.2 mu M), a moderate FXR antagonist was discovered via high-throughput screening. Structure-activity relationship studies indicated that the shape and the lipophilicity of the substituents of the aromatic ring affect the activity dramatically, increasing the shape and the lipophilicity of the substituents of the aromatic ring enhances the potency of FXR antagonists. Especially, when the OH at C2 position of the aromatic ring was replaced by the OBn substituent (analog 2b), its activity could be improved to IC50 = 1.1 +/- 0.1 mu M. Besides, the length of the linker and the tetrazole structure are essential for retaining the activity. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.032
• 作为产物：
  描述：

  4-乙基间苯二酚 在 potassium carbonate 、 potassium iodide 、 zinc(II) chloride 作用下， 以 二甲基亚砜 、 丁酮 为溶剂， 反应 36.0h， 生成 7-(4-acetyl-2-ethyl-5-hydroxyphenoxy)-2,2-dimethylheptanenitrile
  参考文献：
  名称：

  白三烯B4受体拮抗剂：LY255283系列羟基苯乙酮。

  摘要：

  制备了一系列羟基苯乙酮作为白三烯B4（LTB4）受体拮抗剂进行评估，最终以1- [5-乙基-2-羟基-4-[[6-甲基-6-（1H-四唑-5-基）庚基] [氧基]苯基]乙酮（化合物35，LY255283）。使用抑制特异性[3H] LTB4与人PMN结合的测定方法，我们发现活性需要5位非极性取代基的取代。最佳活性是通过3位氢，2位羟基，1位短链烷基酮以及将4位氧与不饱和末端相连的六碳或八碳链实现的功能。选择在结合试验中IC50为87 nM的化合物35进行进一步的临床前评估。

  DOI：

  10.1021/jm00088a018

文献信息

• Anti-inflammatory agents
  申请人：Eli Lilly and Company

  公开号：US04945099A1

  公开（公告）日：1990-07-31

  This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.

  该发明提供苯衍生物，这些衍生物的药物配方，以及使用这些衍生物治疗哺乳动物炎症的方法。
• Method of treating endotoxic shock in mammals
  申请人：Eli Lilly and Company

  公开号：US05294613A1

  公开（公告）日：1994-03-15

  This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.

  这项发明提供苯衍生物、这些衍生物的制药配方，以及使用这些衍生物治疗哺乳动物炎症的方法。
• Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles
  作者：Richard W. Harper、William T. Jackson、Larry L. Froelich、Robert J. Boyd、Timothy E. Aldridge、David K. Herron

  DOI：10.1021/jm00041a021

  日期：1994.7

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.
• AICHAUI, NANCY G.;GOODSON, THEODORE (JR);HERRON, DAVID K.
  作者：AICHAUI, NANCY G.、GOODSON, THEODORE (JR)、HERRON, DAVID K.

  DOI：——

  日期：——
• US4945099A
  申请人：——

  公开号：US4945099A

  公开（公告）日：1990-07-31